Indeed, the striking impact of MEK inhibition in VilCreER;Apcfl/+;KrasG12D/+;Alk5CA mice and organoid models suggests that new, potentially more effective treatment combinations could be found to overcome resistance in emergent TGFβ-high Kras-mutant CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.